Breast Cancer Medications

*generic version available

E experimental

**Chemotherapy Medications**  Learn more >>  More >>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td>Multiple</td>
<td>Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.</td>
</tr>
</tbody>
</table>

**Hormone Therapy Medications**  Learn more >>  More >>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arimidex</td>
<td>anastrozole</td>
<td>Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.</td>
</tr>
<tr>
<td>Aromasin</td>
<td>exemestane</td>
<td>Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.</td>
</tr>
<tr>
<td>Evista</td>
<td>raloxifene</td>
<td>Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Fareston</td>
<td>toremifene</td>
<td>Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.</td>
</tr>
<tr>
<td>Faslodex</td>
<td>fulvestrant</td>
<td>Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.</td>
</tr>
<tr>
<td>Femara</td>
<td>letrozole</td>
<td>Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.</td>
</tr>
<tr>
<td>Lupron</td>
<td>leuprolide</td>
<td>Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>tamoxifen</td>
<td>Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.</td>
</tr>
<tr>
<td>Zoladex</td>
<td>goserelin</td>
<td>Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.</td>
</tr>
</tbody>
</table>

**Immunotherapy Medications** Learn more >> More >>
<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keytruda</td>
<td>pembrolizumab</td>
<td>Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
<tr>
<td>Opdivo</td>
<td>nivolumab</td>
<td>Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced and intermediate or poor risk kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
</tbody>
</table>

Targeted Therapy Medications [Learn more] [More]

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afinitor</td>
<td>everolimus</td>
<td>Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.</td>
</tr>
<tr>
<td>Herceptin</td>
<td>trastuzumab</td>
<td>Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer and gastric or esophageal carcinoma that overexpresses human epidermal growth factor receptor 2.</td>
</tr>
<tr>
<td>Ibrance</td>
<td>palbociclib</td>
<td>Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Kadcyla</td>
<td>ado-trastuzumab emtansine</td>
<td>Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.</td>
</tr>
<tr>
<td>Kisqali</td>
<td>ribociclib</td>
<td>Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.</td>
</tr>
<tr>
<td>Lynparza</td>
<td>olaparib</td>
<td>Lynparza is a PARP inhibitor approved for first-line maintenance treatment of ovarian cancer in women with harmful BRCA mutations, maintenance treatment of recurrent ovarian cancer that is responding to chemotherapy, previously treated advanced ovarian cancer in patients with BRCA mutations, and previously treated HER2-negative metastatic breast cancer in people with BRCA mutations.</td>
</tr>
<tr>
<td>Nerlynx</td>
<td>neratinib</td>
<td>Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.</td>
</tr>
<tr>
<td>Perjeta</td>
<td>pertuzumab</td>
<td>Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.</td>
</tr>
<tr>
<td>Piqray</td>
<td>alpelisib</td>
<td>Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.</td>
</tr>
<tr>
<td>Talzenna</td>
<td>talazoparib</td>
<td>Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Tykerb</td>
<td>lapatanib</td>
<td>Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.</td>
</tr>
<tr>
<td>Verzenio</td>
<td>abemaciclib</td>
<td>Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.</td>
</tr>
<tr>
<td>Vitrakvi</td>
<td>laronetribin</td>
<td>Vitrakvi is a tropomyosin receptor kinase (TRK) inhibitor that works against cancers anywhere in the body with NTRK gene fusions.</td>
</tr>
</tbody>
</table>

**DRUG** **Chemotherapy**

**GENERIC NAME** Multiple

**DRUG INDICATION**

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, [click here](#).

**DRUG** **Arimidex**

**GENERIC NAME** anastrozole

**DRUG INDICATION**

Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.

**DRUG** **Aromasin**

**GENERIC NAME** exemestane

**DRUG INDICATION**

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

**DRUG** **Evista**

**GENERIC NAME** raloxifene

**DRUG INDICATION**

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

**DRUG** **Fareston**

**GENERIC NAME** toremifene
**DRUG Fareston**
**DRUG INDICATION**
Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.

**DRUG Faslodex**
**GENERIC NAME** fulvestrant
**DRUG INDICATION**
Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.

**DRUG Femara**
**GENERIC NAME** letrozole
**DRUG INDICATION**
Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.

**DRUG Lupron**
**GENERIC NAME** leuprolide
**DRUG INDICATION**
Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

**DRUG Tamoxifen**
**GENERIC NAME** tamoxifen
**DRUG INDICATION**
Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

**DRUG Zoladex**
**GENERIC NAME** goserelin
**DRUG INDICATION**
Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

**DRUG Keytruda**
**GENERIC NAME** pembrolizumab
DRUG Keytruda
DRUG INDICATION
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION
Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced and intermediate or poor risk kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Afinitor
GENERIC NAME everolimus
DRUG INDICATION
Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

DRUG Herceptin
GENERIC NAME trastuzumab
DRUG INDICATION
Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer and gastric or esophageal carcinoma that overexpresses human epidermal growth factor receptor 2.

DRUG Ibrance
GENERIC NAME palbociclib
DRUG INDICATION
Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Kadcyla
GENERIC NAME ado-trastuzumab emtansine
DRUG INDICATION
Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy and for adjuvant (post-surgery) therapy for early breast cancer.
DRUG Kisqali
GENERIC NAME ribociclib
DRUG INDICATION
Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Lynparza
GENERIC NAME olaparib
DRUG INDICATION
Lynparza is a PARP inhibitor approved for first-line maintenance treatment of ovarian cancer in women with harmful BRCA mutations, maintenance treatment of recurrent ovarian cancer that is responding to chemotherapy, previously treated advanced ovarian cancer in patients with BRCA mutations, and previously treated HER2-negative metastatic breast cancer in people with BRCA mutations.

DRUG Nerlynx
GENERIC NAME neratinib
DRUG INDICATION
Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

DRUG Perjeta
GENERIC NAME pertuzumab
DRUG INDICATION
Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

DRUG Piqray
GENERIC NAME alpelisib
DRUG INDICATION
Piqray is a PI3K kinase inhibitor approved for the treatment of postmenopausal women, and men, with HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.

DRUG Talzenna
GENERIC NAME talazoparib
DRUG INDICATION
Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

DRUG Tykerb
GENERIC NAME lapatanib
**DRUG Tykerb**  
**DRUG INDICATION**  
Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.

**DRUG Verzenio**  
**GENERIC NAME** abemaciclib  
**DRUG INDICATION**  
Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.

**DRUG Vitrakvi**  
**GENERIC NAME** larotrectinib  
**DRUG INDICATION**  
Vitrakvi is a tropomyosin receptor kinase (TRK) inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

© 2019 Smart + Strong All Rights Reserved.  
https://www.cancerhealth.com/drug_charts/breast-cancer-medications-drugs